TLSA — Tiziana Life Sciences Share Price
Last trade - 00:00- $45.00m
- $27.24m
- 33
- 20
- 24
- 15
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.3 | ||
| Price to Tang. Book | 2.3 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -73.61% | ||
| Return on Equity | -50.61% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company. The Company develops transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Crohn's Disease and KRAS+ NSCLC. Its pipeline candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501) and Milciclib (TZLS-201). Foralumab (TZLS-401) is a fully human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn’s and neurodegenerative diseases. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.
Directors
- Gabriele Cerrone CHM (48)
- Kunwar Shailubhai CEO (63)
- Neil Graham OTH (62)
- John Brancaccio NID (73)
- Willy Simon NID (69)
- Last Annual
- December 31st, 2022
- Last Interim
- December 31st, 2022
- Incorporated
- March 20th, 2020
- Public Since
- July 14th, 2008
- No. of Employees
- 9
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 102,272,614
- Address
- 3Rd Floor, 11-12 St. James's Square, LONDON, SW1Y 4LB
- Web
- https://www.tizianalifesciences.com/
- Phone
- +44 2074952379
- Auditors
- PKF Littlejohn LLP
Latest News for TLSA
Upcoming Events for TLSA
Full Year 2023 Tiziana Life Sciences Ltd Earnings Release
Similar to TLSA
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
As of Today at 19:22 UTC, shares in Tiziana Life Sciences are trading at $0.44. This share price information is delayed by 15 minutes.
Shares in Tiziana Life Sciences last closed at $0.44 and the price had moved by -59.26% over the past 365 days. In terms of relative price strength the Tiziana Life Sciences share price has underperformed the S&P500 Index by -67.1% over the past year.
The overall consensus recommendation for Tiziana Life Sciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Tiziana Life Sciences does not currently pay a dividend.
Tiziana Life Sciences does not currently pay a dividend.
Tiziana Life Sciences does not currently pay a dividend.
To buy shares in Tiziana Life Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.44, shares in Tiziana Life Sciences had a market capitalisation of $45.00m.
Here are the trading details for Tiziana Life Sciences:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: TLSA
Based on an overall assessment of its quality, value and momentum Tiziana Life Sciences is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Tiziana Life Sciences is $3.00. That is 581.82% above the last closing price of $0.44.
Analysts covering Tiziana Life Sciences currently have a consensus Earnings Per Share (EPS) forecast of -$0.15 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Tiziana Life Sciences. Over the past six months, its share price has underperformed the S&P500 Index by -53.05%.
As of the last closing price of $0.44, shares in Tiziana Life Sciences were trading -27.62% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Tiziana Life Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.44.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Tiziana Life Sciences' management team is headed by:
- Gabriele Cerrone - CHM
- Kunwar Shailubhai - CEO
- Neil Graham - OTH
- John Brancaccio - NID
- Willy Simon - NID